CN103272122A

CN103272122A - Traditional Chinese medicinal composition for treating Chronic aplastic anemia

Info

Publication number: CN103272122A
Application number: CN2013102166632A
Authority: CN
Inventors: 刘建华
Original assignee: Individual
Current assignee: Individual
Priority date: 2013-05-23
Filing date: 2013-05-23
Publication date: 2013-09-04
Anticipated expiration: 2033-05-23
Also published as: CN103272122B

Abstract

The invention discloses a traditional Chinese medicinal composition for treating chronic aplastic anemia. The chronic aplastic anemia belongs to the traditional Chinese medicinal field of 'blood deficiency', 'blood exhaustion', 'consumptive disease', 'blood trouble' and the like, is mostly caused by internal injury and asthenic disease, is diseased in marrow, has main lesion in kidney and is closely related to spleen; and the chronic aplastic anemia is caused by primary and secondary deficiencies and lack of essence and blood origins. Consequently, the traditional Chinese medicinal composition is prepared into decoction through selecting traditional Chinese medicines such as ventilago leiocarpa benth, bicolor limonium, savia miltiorrhiza, human placentophagy, radix rehmanniae preparata, rhizoma polygonati, potentilla anserine, rhizoma atractylodis macrocephalae, tortoise shell, cypripedium margaritaceum franch and herba ecliptae. Clinical trial experiments prove that the total efficiency of the composition reaches 89.4%, and the composition is obviously better than a control group.

Description

A kind of Chinese medicine composition for the treatment of chronic aplastic anemia

Technical field

The present invention relates to a kind of Chinese medicine composition, relate in particular to a kind of Chinese medicine composition for the treatment of chronic aplastic anemia.

Background technology

Aplastic anemia (from) be the multi-functional hematopoietic stem cell disease of bone marrow, hemopoietic tissue nonfunction syndrome reduces with the full cell of peripheral blood, the low hypertrophy bone marrow of companion, the bone marrow hematogenesis tissue is substituted by fatty tissue, and hematopoietic cell excessively is reduced to feature.Western medical treatment impenetrability anemia more generally adopts hormone medicine, but it is general often to produce effects, and can only keep reluctantly at last.Yet entering human body, these hormones but can cause liver injury by liver, it is hyperfunction that hepatic injury can increase the weight of spleen infringement, splenomegaly, spleen again, the interior platelet of spleen is hidden to be increased, the peripheral circulation thrombocytopenia, taking for a long time not only has side effect very big, and can increase the weight of thrombocytopenia disease and other class complication.

Summary of the invention

The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of chronic aplastic anemia.Primary disease belongs to categories such as the traditional Chinese medical science " blood deficiency ", " blood depletion ", " asthenia ", " blood disorder ", and to belong to internal injury deficient pathogenic more, and is sick at bone marrow, and main dirty genus kidney is closely related with spleen; Because of the elder generation's deficiency day after tomorrow, the biochemical weary source of essence and blood.

The objective of the invention is to be achieved through the following technical solutions, the Chinese medicine composition of this treatment chronic aplastic anemia is made by following parts by weight of Chinese traditional medicine: Radix seu Caulis Verntilaginis Leiocarpae 10-30 part, Herba Limoii Bicoloris 5-25 part, Herba Wedeliae Wallichii 7-15 part, Placenta Hominis 10-16 part, Radix Rehmanniae Preparata 11-17 part, Rhizoma Polygonati 11-15 part, Radix potentillae anserinae 8-18 part, Rhizoma Atractylodis Macrocephalae 9-20 part, Carapax Et Plastrum Testudinis 6-10 part, Herba Cyperipedii Margaritacei 7-23 part, Herba Ecliptae 12-14 part.

Preferably, 20 parts of Radix seu Caulis Verntilaginis Leiocarpae, 15 parts of Herba Limoii Bicoloriss, 11 parts of Herba Wedeliae Wallichii, 13 parts of Placenta Hominiss, 14 parts of Radix Rehmanniae Preparata, 13 parts of Rhizoma Polygonatis, 14 parts of Radix potentillae anserinae, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Carapax Et Plastrum Testudiniss, 15 parts of Herba Cyperipedii Margaritaceis, 13 parts of Herba Ecliptaes.

Preparation method is by traditional preparation method, and decocting is made decoction.

In the side: Radix seu Caulis Verntilaginis Leiocarpae, Herba Limoii Bicoloris, Herba Wedeliae Wallichii benefiting vital QI and blood, dispelling wind and removing obstruction in the collateral, the spleen reinforcing stomach invigorating is enriched blood and is invigorated blood circulation; Placenta Hominis, Radix Rehmanniae Preparata, Rhizoma Polygonati, Radix potentillae anserinae the kidney warming are mended smart, benefiting QI and nourishing blood, and the YIN nourishing of enriching blood, beneficial essence is filled out marrow, the nourishing kidney lung moistening; The Rhizoma Atractylodis Macrocephalae, Carapax Et Plastrum Testudinis, Herba Cyperipedii Margaritacei, Herba Ecliptae air making-up and spleen enlivening, nourishing YIN for suppressing the hyperactive YANG, the reinforcing the heart of nourishing blood, and QI and blood, tonifying liver kidney yin.

Clinical data

1, physical data 170 routine patients are my inpatient of institute of in December, 2007～2009 year December.Be divided into treatment group and matched group at random, 85 examples are organized in treatment, male 47 examples wherein, women 38 examples, 4～65 years old age, 4～15 years old 20 example wherein, 16～51 years old 54 example, 52～65 years old 11 example, The median age 29 years old.The course of disease 4 days～210 months, average 425 days.SAA18 example wherein, the CAA67 example; Matched group 85 examples, male 46 examples wherein, women 39 examples, 10～70 years old age, 5～13 years old 21 example wherein, 14～50 years old 52 example, 51～70 years old 12 example, The median age 33 years old, the course of disease 5 days～200 months, average 410 days, SAA20 example wherein, the CAA65 example; Two groups of patients age, the course of disease, the degree that is in a bad way, etc. aspect there was no significant difference all, have comparability.

2, diagnostic criteria (1) clinical manifestation: morbidity is slow, anemia, infection, hemorrhage all lighter.(2) hemogram: the hemoglobin decrease speed is slower, and reticulocyte, leukocyte, neutrophilic granulocyte and platelet value are high than acute aplastic anemia often; (3) bone marrow smear: 3 are or two are minimizing, and at least 1 position hypertrophy is bad, and is good as hypertrophy, often has late children red (charcoal nuclear) ratio to raise in the red system, and megalokaryocyte obviously reduces, and non-hematopoietic cell and adipose cell increase in the bone marrow granule; (4) in the course of disease as sb.'s illness took a turn for the worse, clinical, hemogram and bone marrow smear are similar to acute aplastic anemia, the type of then weighing aplastic anemia II type.

3, Therapeutic Method treatment group is taken Chinese medicine composition of the present invention, every day potion, the every day of sub-service sooner or later; Matched group CAA uses stanozolol 6mg/d or pacifies male 40mg/d, and SAA uses stanozolol 6mg/d or pacifies male 40mg/d, ring spore A (North China Pharmaceutical Factory's production) 100mg-200mg/d, and two groups of equal two weeks are a course for the treatment of.

4, criterion of therapeutical effect clinical cure: anemia and bleeding disappear, and hemoglobin man reaches 120g/L, the woman reaches 100g/L, and leukocyte reaches 4 * 109/L, and platelet reaches 80 * 109/L, follows up a case by regular visits to more than 1 year and does not send out; Alleviate: anemia and bleeding disappear, and hemoglobin man reaches 120g/L, the woman reaches 100g/L, and leukocyte reaches 3.5 * 109/L, and platelet also has to a certain degree to be increased, and follow up a case by regular visits to 3 months stable disease or continue progressive; Obviously progressive: anemia and bleeding are clearly better, and do not transfuse blood, and hemoglobin is treated in preceding 1 month modal value and increased and reach 30g/L, and can keep 3 months; Invalid: after fully treating, symptom, hemogram do not reach obvious progress.

5, (1) two group for the treatment of back of therapeutic outcome curative effect relatively sees Table 1.

Table 1 liang group treatment back curative effect relatively

Two groups are compared P＜0.05

Treatment group clinical recovery, total effective rate obviously are better than matched group, have statistical significance.

After (2) two groups of treatments, compare with matched group, the treatment group sees Table 2 improving difference variation on WBC, the HGB index.

Table 2 liang group is in the comparison that improves on WBC, the HGB index

The comparison of two groups of routine blood tests self is compared HGB and is changed before and after two groups of patient treatments, difference all has statistical significance (P＜0.01).

Relatively (x ± s pg/ml), sees Table 3 to (3) two groups of serum TNF-alpha levels.

Table 3 liang group serum TNF-alpha levels comparison (x ± s, pg/ml)

The specific embodiment

Embodiment one: take by weighing Radix seu Caulis Verntilaginis Leiocarpae 20g, Herba Limoii Bicoloris 15g, Herba Wedeliae Wallichii 11g, Placenta Hominis 13g, Radix Rehmanniae Preparata 14g, Rhizoma Polygonati 5g, Radix potentillae anserinae 14g, Rhizoma Atractylodis Macrocephalae 15g, Carapax Et Plastrum Testudinis 8g, Herba Cyperipedii Margaritacei 15g, Herba Ecliptae 13g, decocting is made decoction.

Embodiment two: take by weighing Radix seu Caulis Verntilaginis Leiocarpae 30g, Herba Limoii Bicoloris 5g, Herba Wedeliae Wallichii 15g, Placenta Hominis 10g, Radix Rehmanniae Preparata 11g, Rhizoma Polygonati 7g, Radix potentillae anserinae 8g, Rhizoma Atractylodis Macrocephalae 20g, Carapax Et Plastrum Testudinis 6g, Herba Cyperipedii Margaritacei 23g, Herba Ecliptae 12g, decocting is made decoction.

Embodiment three: take by weighing Radix seu Caulis Verntilaginis Leiocarpae 10g, Herba Limoii Bicoloris 25g, Herba Wedeliae Wallichii 71g, Placenta Hominis 16g, Radix Rehmanniae Preparata 17g, Rhizoma Polygonati 3g, Radix potentillae anserinae 18g, Rhizoma Atractylodis Macrocephalae 9g, Carapax Et Plastrum Testudinis 10g, Herba Cyperipedii Margaritacei 7g, Herba Ecliptae 14g, decocting is made decoction.

Claims

1. Chinese medicine composition for the treatment of chronic aplastic anemia is characterized in that this Chinese medicine composition made by following parts by weight of Chinese traditional medicine: Radix seu Caulis Verntilaginis Leiocarpae 10-30 part, Herba Limoii Bicoloris 5-25 part, Herba Wedeliae Wallichii 7-15 part, Placenta Hominis 10-16 part, Radix Rehmanniae Preparata 11-17 part, Rhizoma Polygonati 11-15 part, Radix potentillae anserinae 8-18 part, Rhizoma Atractylodis Macrocephalae 9-20 part, Carapax Et Plastrum Testudinis 6-10 part, Herba Cyperipedii Margaritacei 7-23 part, Herba Ecliptae 12-14 part.

2. a kind of Chinese medicine composition for the treatment of chronic aplastic anemia according to claim 1 is characterized in that this Chinese medicine composition made by following parts by weight of Chinese traditional medicine: 20 parts of Radix seu Caulis Verntilaginis Leiocarpae, 15 parts of Herba Limoii Bicoloriss, 11 parts of Herba Wedeliae Wallichii, 13 parts of Placenta Hominiss, 14 parts of Radix Rehmanniae Preparata, 13 parts of Rhizoma Polygonatis, 14 parts of Radix potentillae anserinae, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Carapax Et Plastrum Testudiniss, 15 parts of Herba Cyperipedii Margaritaceis, 13 parts of Herba Ecliptaes.